G Protein News and Research

RSS

AFQ056 drug improves symptoms in Fragile X patients: Study

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise according to a new study published in the January issue of Science Translational Medicine.

9 Jan 2011

Green tea may help in Alzheimer’s disease: Study

A new study finds that a cup of green tea may protect against Alzheimer’s disease and other forms of dementia. The researchers looked at the effects of a concentrated green tea extract that had been treated in the laboratory to mimic the effects of normal digestion.

9 Jan 2011

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced preliminary results indicating that their human Alzheimer's disease (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients.

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Cells that give rise to neurons maintain high levels of ROS

For years, the majority of research on reactive oxygen species (ROS) - ions or very small molecules that include free radicals - has focused on how they damage cell structure and their potential link to stroke, cardiovascular disease and other illnesses.

7 Jan 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

7 Jan 2011

Researchers identify genetic mutation responsible for acromegaly disease

An international research team, spearheaded by scientists from the London School of Medicine and Dentistry, has identified the genetic mutation responsible for a disease known as "gigantism" or acromegaly.

7 Jan 2011

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Antigenics announces name change to Agenus

Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.

6 Jan 2011

Scientists develop novel technology to detect immune molecules specific to Alzheimer's disease

Scientists from the Florida campus of The Scripps Research Institute, have developed a novel technology that is able to detect the presence of immune molecules specific to Alzheimer's disease in patients' blood samples. While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.

6 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system.

6 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

G Protein News and Research

AFQ056 drug improves symptoms in Fragile X patients: Study

Green tea may help in Alzheimer’s disease: Study

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Cells that give rise to neurons maintain high levels of ROS

HRG protein inhibits tumor growth and metastasis: Study

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Researchers identify genetic mutation responsible for acromegaly disease

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

GT Life Sciences and BGI complete CHO-K1 genome sequencing

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Antigenics announces name change to Agenus

Scientists develop novel technology to detect immune molecules specific to Alzheimer's disease

New technique to analyze and quantify changes in protein

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

Mutated TDP-43 can cause neurons to die: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News